Le Lézard
Classified in: Health, Science and technology, Business
Subject: TNM

QHR Technologies Completes Acquisition of Jonoke Assets



KELOWNA, BC, July 2, 2015 /CNW/ - (TSX-V: QHR) QHR Corporation ("QHR" or the "Company"), a leader in the Canadian Healthcare Information Technology sector, is pleased to announce that its wholly-owned subsidiary, QHR Technologies Inc., has completed its acquisition of the healthcare assets of Jonoke Software Development Inc. ("Jonoke"), including its proprietary Electronic Medical Record ("EMR") software and its clients. 

As previously announced the all-cash purchase price is tied to an earn-out paid over a period of time during which QHR and Jonoke will be working together to transition Jonoke's clients to QHR's Accuro®EMR system. The earn-out is estimated to be under $500,000 over a three year period.

Jonoke is a privately owned company based in Edmonton, Alberta, with a current client base of over 750 physicians located in Alberta, Manitoba and Ontario which currently generates approximately $1 million in annual support revenues for the Jonoke products.  QHR intends to transition these clients to its Accuro platform.

The Company expects that with the existing Jonoke revenue, this acquisition will be accretive to QHR's earnings in the third quarter of this year.

On behalf of the Board of Directors

Mike Checkley, President & CEO

About QHR Corporation

QHR is a leader in Healthcare Technology, empowering providers and connecting patients.  With an 11-year track record offering what is now the single leading Electronic Medical Records platform in Canada, QHR has a suite of complementary offerings that empower health professionals and drive the Company's growth. The Company's technologies and services enable secure medical records management for clinical environments, empower health providers with tools for virtual care including secure video and messaging, and tools for clinic management including scheduling, billing, and patient management, Health providers choose QHR to drive efficiencies within their practice and improve the quality of care delivered to patients.

Legal Notice Regarding Forward Looking Statements

This news release may contain "forward looking statements" within the meaning of applicable Canadian securities legislation. These statements are subject to risks that may cause the actual results to be materially different in future periods from those expressed or implied by such forward looking statement. Forward-looking statements in this news release include those concerning the Company's intent to transition the Jonoke clients to its Accuro Platform during the earn-out period, its anticipation that those transitions will be smooth and seamless.

Risks that may prevent or delay the forward looking statements from coming to fruition include that Jonoke clients might choose not to transition to the Accuro platform, industry regulation; competition; the availability of capital and key personnel, obsolescence, workflow and market factors that may increase costs. QHR is a technology business development enterprise where investment and product enhancements must be carefully managed to achieve long-term revenue growth and profitability. It is the Company's policy not to update forward looking statements except to the extent required under applicable securities laws. Further information on the Company is available at www.sedar.com or at the Company's website, www.QHRtechnologies.com.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE QHR Corporation


These press releases may also interest you

at 02:00
Kyowa Hakko Kirin Co., Ltd. (Tokyo: 4151, President and CEO: Nobuo Hanai, "Kyowa Hakko Kirin") announced today that the results of the Global Phase 3 study (MAVORIC: Mogamulizumab anti-CCR4 Antibody Versus ComparatOR In CTCL) investigating the use of...

at 02:00
Interim data provides important real world insights into the treatment pathway of patients in the UK with chronic myeloid leukaemia    In patients with a suboptimal response in first line; higher rates of subsequent ELN optimal response were...

at 01:30
Capio is strengthening its involvement in the development of digital healthcare solutions by investing MSEK 49 in the new share issue of MSEK 100 that was announced by the e-health provider Doctrin today. By investing, Capio is participating in the...

at 01:23
Nordic Nanovector ASA (OSE: NANO) has presented updated results from its LYMRIT 37-01 Phase 1/2 clinical study of Betalutin® (177Lu-satetraxetan-lilotomab) in patients with relapsed/refractory (R/R) indolent NHL (iNHL) at the 59th Annual ASH meeting...

10 déc 2017
Blessed Herbs Cafe and Mount Zion Rastafarian Church founder and practicing Rasta George Metropoulos today announced the launch of the organization's first holiday season food and cash drive. Directly benefiting the neighborhood's less fortunate...

10 déc 2017
A new article published today in The New England Journal of Medicine shows that 42 percent of diffuse large B cell lymphoma patients treated with axicabtagene ciloleucel, offered commercially under the brand name Yescartatm, remain in remission 15...




News published on 2 july 2015 at 07:30 and distributed by: